Pfizer, Inc.
Every calculator, already run for PFE
Open the full toolkit →You have the numbers on PFE. Get the argument.
A written report on which of these readings actually decide the outcome for Pfizer, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
28 analysts covering PFEAnalyst Price Target Disagreement for Pfizer, Inc.
Wall Street's bull case implies +33% from the current price; the bear case implies -7%. A 40% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Pfizer, Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeu…
PFE — frequently asked
Is PFE a buy right now?
Wall Street's consensus rating on Pfizer, Inc. is Buy across 28 analysts, with a mean price target of $28.64 (+7% vs. the current $26.79). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is PFE overvalued?
PFE trades at 35.3x trailing earnings, against a DCF fair value of $85 per share. The current price implies -8% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is PFE's next earnings date?
Pfizer, Inc. is next scheduled to report earnings around Nov 3, 2026. A full PFE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Pfizer, Inc.?
Analysts covering Pfizer, Inc. (PFE) range from a bear-case target of $25.00 to a bull-case high of $35.75, with a mean consensus target of $28.64 across 26 analysts. The spread of $10.75 (40% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Pfizer, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Pfizer, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full PFE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Pfizer, Inc., in minutes. 3 free reports included with every account — no credit card required.